This company listing is no longer active
BDRX Stock Overview
A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.037 |
| 52 Week High | UK£3.18 |
| 52 Week Low | UK£0.038 |
| Beta | 1.13 |
| 11 Month Change | -76.56% |
| 3 Month Change | -90.38% |
| 1 Year Change | -98.47% |
| 33 Year Change | -99.59% |
| 5 Year Change | -99.97% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| BDRX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -16.7% | -1.7% | -1.0% |
| 1Y | -98.5% | -19.2% | 6.9% |
Return vs Industry: BDRX underperformed the UK Biotechs industry which returned -15.3% over the past year.
Return vs Market: BDRX underperformed the UK Market which returned -1% over the past year.
Price Volatility
| BDRX volatility | |
|---|---|
| BDRX Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BDRX's share price has been volatile over the past 3 months.
Volatility Over Time: BDRX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 20 | Stephen Stamp | www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Biodexa Pharmaceuticals Plc Fundamentals Summary
| BDRX fundamental statistics | |
|---|---|
| Market cap | UK£3.55m |
| Earnings (TTM) | -UK£5.37m |
| Revenue (TTM) | UK£645.00k |
5.5x
P/S Ratio-0.7x
P/E RatioIs BDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDRX income statement (TTM) | |
|---|---|
| Revenue | UK£645.00k |
| Cost of Revenue | UK£4.65m |
| Gross Profit | -UK£4.01m |
| Other Expenses | UK£1.36m |
| Earnings | -UK£5.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | -621.55% |
| Net Profit Margin | -832.09% |
| Debt/Equity Ratio | 0% |
How did BDRX perform over the long term?
See historical performance and comparison